MedTrace Logo

Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)

NCT00405964 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 716

Last updated 2024-05-20

Study results available
· View outcomes & findings →

Summary

This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)

Conditions

  • Allergic Rhinitis

Interventions

DRUG

5-mg Desloratadine

5-mg Desloratadine tablet, once daily for 12 weeks

DRUG

Placebo tablet

Placebo tablet, once daily for 12 weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-04-30
Completion
2008-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405964 on ClinicalTrials.gov